nach oben

Erschienen in:

22.01.2024 | Review

The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis

verfasst von: Hadis Razmaray, Ehsan Nasiri, Pouya Vakilipour, Soroush Morsali, Afshin Moradi, Asal Ebrahimian, Sahel Rashidi, Reza Mosaddeghi-Heris, Saeed Sadigh-Eteghad, Amirreza Naseri

Erschienen in: Inflammopharmacology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Through the antioxidant and anti-inflammation pathways, melatonin is proposed as a safe and effective intervention in neurological diseases. This study aims to evaluate the effects of melatonin supplementation on the neurobehavioral and clinical outcomes in animal models of multiple sclerosis (MS).

Methods

This study was conducted following the PRISMA statement. Animal studies that reported the effects of melatonin in preclinical MS models, including the experimental autoimmune encephalomyelitis (EAE) and cuprizone model for demyelination are included in this study. A systematic search in PubMed, Web of Science, Embase, and Scopus up was conducted in April 2023. The collaborative Approach to Meta-Analysis and Review of Animal Experimental Studies (CAMARADES) critical appraisal tool was used for the quality assessment of the studies and the quantitative synthetizes were conducted using the comprehensive meta-analysis software.

Results

Out of 542 studies, finally 21 studies, including 14 studies in the EAE model and 7 studies of the toxic demyelination method with cuprizone were included. The route of administration was intraperitoneal in 18 studies, oral in 2 studies, and subcutaneous in 1 study. The quantitative synthesis of the EAE clinical severity scale was associated with significant differences (standardized mean difference [SDM]: − 2.52; − 3.61 to − 1.42; p value < 0.01). In subgroup analyses, the difference was statistically significant in the mouse subgroup (SMD: − 2.60; − 3.74 to − 1.46; p value < 0.01).

Discussion

This study encountered that melatonin may be associated with improved behavioral and cognitive outcomes of preclinical models of MS with acceptable safety profiles.

Funding

The research was supported by the Student Research Committee, Tabriz University of Medical Sciences (grant number: 71005).

Abo Taleb HA, Alghamdi BS (2020) Neuroprotective Effects of Melatonin during Demyelination and Remyelination Stages in a Mouse Model of Multiple Sclerosis [Article]. J Mol Neurosci 70(3):386–402. https://doi.org/10.1007/s12031-019-01425-6CrossRefPubMed

Alghamdi BS, AboTaleb HA (2020) Melatonin improves memory defects in a mouse model of multiple sclerosis by up-regulating cAMP-response element-binding protein and synapse-associated proteins in the prefrontal cortex. J Integr Neurosci 19(2):229–237CrossRefPubMed

Álvarez-Sánchez N, Cruz-Chamorro I, López-González A, Utrilla JC, Fernández-Santos JM, Martínez-López A, Lardone PJ, Guerrero JM, Carrillo-Vico A (2015) Melatonin controls experimental autoimmune encephalomyelitis by altering the T effector/regulatory balance [Article]. Brain, Behavior Immunity 50:101–114. https://doi.org/10.1016/j.bbi.2015.06.021CrossRefPubMed

Burrows DJ, McGown A, Jain SA, De Felice M, Ramesh TM, Sharrack B, Majid A (2019) Animal models of multiple sclerosis: From rodents to zebrafish. Mult Scler 25(3):306–324. https://doi.org/10.1177/1352458518805246CrossRefPubMed

Chen SJ, Huang SH, Chen JW, Wang KC, Yang YR, Liu PF, Lin GJ, Sytwu HK (2016) Melatonin enhances interleukin-10 expression and suppresses chemotaxis to inhibit inflammation in situ and reduce the severity of experimental autoimmune encephalomyelitis [Article]. Int Immunopharmacol 31:169–177. https://doi.org/10.1016/j.intimp.2015.12.020CrossRefPubMed

Dokoohaki S, Ghareghani M, Ghanbari A, Farhadi N, Zibara K, Sadeghi H (2017) Corticosteroid therapy exacerbates the reduction of melatonin in multiple sclerosis. Steroids 128:32–36. https://doi.org/10.1016/j.steroids.2017.10.006CrossRefPubMed

Escribano BM, Muñoz-Jurado A, Caballero-Villarraso J, Valdelvira ME, Giraldo AI, Paz-Rojas E, Gascón F, Santamaría A, Agüera E, Túnez I (2022) Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis [Article]. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2022.103520CrossRefPubMed

Ghareghani M, Dokoohaki S, Ghanbari A, Farhadi N, Zibara K, Khodadoust S, Parishani M, Ghavamizadeh M, Sadeghi H (2017) Melatonin exacerbates acute experimental autoimmune encephalomyelitis by enhancing the serum levels of lactate: A potential biomarker of multiple sclerosis progression [Article]. Clin Exp Pharmacol Physiol 44(1):52–61. https://doi.org/10.1111/1440-1681.12678CrossRefPubMed

Ghareghani M, Reiter RJ, Zibara K, Farhadi N (2018a) Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis: A New Mechanistic Pathway. Front Immunol 9:2484. https://doi.org/10.3389/fimmu.2018.02484CrossRefPubMedPubMedCentral

Ghareghani M, Scavo L, Arnoult D, Zibara K, Farhadi N (2018b) Melatonin therapy reduces the risk of osteoporosis and normalizes bone formation in multiple sclerosis. Fundam Clin Pharmacol 32(2):181–187. https://doi.org/10.1111/fcp.12337CrossRefPubMed

Ghareghani M, Zibara K, Sadeghi H, Farhadi N (2018c) Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis [Article]. Cell Mol Neurobiol 38(5):1145–1151. https://doi.org/10.1007/s10571-018-0580-yCrossRefPubMed

Ghareghani M, Scavo L, Jand Y, Farhadi N, Sadeghi H, Ghanbari A, Mondello S, Arnoult D, Gharaghani S, Zibara K (2019) Melatonin therapy modulates cerebral metabolism and enhances remyelination by increasing PDK4 in a mouse model of multiple sclerosis. Front Pharmacol 10:147CrossRefPubMedPubMedCentral

Ghareghani M, Farhadi Z, Rivest S, Zibara K (2022) PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis. Front Immunol 13:862316. https://doi.org/10.3389/fimmu.2022.862316CrossRefPubMedPubMedCentral

Ghareghani M, Pons V, Laflamme N, Zibara K, Rivest S (2023a) Author Correction: Inhibiting nighttime melatonin and boosting cortisol increase patrolling monocytes, phagocytosis, and myelination in a murine model of multiple sclerosis. Exp Mol Med 55(2):485–486. https://doi.org/10.1038/s12276-023-00948-8CrossRefPubMedPubMedCentral

Ghareghani M, Zibara K, Rivest S (2023b) Melatonin and vitamin D, two sides of the same coin, better to land on its edge to improve multiple sclerosis. Proc Natl Acad Sci U S A 120(14):e2219334120. https://doi.org/10.1073/pnas.2219334120CrossRefPubMedPubMedCentral

Gharib D, Rashed L, Yousuf A, El-Shawwa M, Saber S, Ibrahim B, Kamel M (2022) Therapeutic Effect of Microvesicles Derived From BM-MSCS Transplantation And/Or Melatonin In Cuprizone Model of Multiple Sclerosis: A Pharmacodynamic Biochemical Assay. Egypt J Chem 65(10):153–169. https://doi.org/10.21608/ejchem.2022.112611.5107CrossRef

Gold R, Linington C, Lassmann H (2006) Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 129(Pt 8):1953–1971. https://doi.org/10.1093/brain/awl075CrossRefPubMed

Hawkes CH, Baker MD, Pohl D, Lechner-Scott J, Levy M, Giovannoni G (2021) Melatonin and multiple sclerosis. Mult Scler Relat Disord 51:103032. https://doi.org/10.1016/j.msard.2021.103032CrossRefPubMed

Jallouli S, Ghroubi S, Dhia IB, Yahia A, Elleuch MH, Sakka S, Mhiri C, Hammouda O (2022) Effect of melatonin intake on postural balance, functional mobility and fall risk in persons with multiple sclerosis: a pilot study. Int J Neurosci. https://doi.org/10.1080/00207454.2022.2090353CrossRefPubMed

Jand Y, Ghahremani MH, Ghanbari A, Ejtemaei-Mehr S, Guillemin GJ, Ghazi-Khansari M (2022) Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway. Sci Rep 12(1):15963. https://doi.org/10.1038/s41598-022-20164-0CrossRefPubMedPubMedCentral

Kang JC, Ahn M, Kim YS, Moon C, Lee Y, Wie MB, Lee YJ, Shin T (2001) Melatonin ameliorates autoimmune encephalomyelitis through suppression of intercellular adhesion molecule-1. J Vet Sci 2(2):85–89CrossRefPubMed

Kashani IR, Rajabi Z, Akbari M, Hassanzadeh G, Mohseni A, Eramsadati MK, Rafiee K, Beyer C, Kipp M, Zendedel A (2014) Protective effects of melatonin against mitochondrial injury in a mouse model of multiple sclerosis. Exp Brain Res 232(9):2835–2846. https://doi.org/10.1007/s00221-014-3946-5. ([RETRACTEDARTICLE])CrossRefPubMed

Kern S, Geiger M, Paucke M, Kästner A, Akgün K, Ziemssen T (2019) Clinical relevance of circadian melatonin release in relapsing-remitting multiple sclerosis. J Mol Med (Berl) 97(11):1547–1555. https://doi.org/10.1007/s00109-019-01821-wCrossRefPubMed

Labunets I, Utko N, Toporova O, Pokholenko I, Panteleymonova T, Litoshenko Z, Butenko G (2021a) The effects of combined administration of human umbilical cord-derived multipotent mesenchymal stromal cells and melatonin or fibroblast growth factor-2 to aged mice with a toxic cuprizone model of demyelination [Article]. Cell Organ Transplant 9(1):4–11. https://doi.org/10.22494/cot.v9i1.116CrossRef

Labunets IF, Utko NA, Toporova OK (2021b) Effects of Multipotent Mesenchymal Stromal Cells of the Human Umbilical Cord and Their Combination with Melatonin in Adult and Aging Mice with a Toxic Cuprizone Model of Demyelination [Article]. Adv Gerontol 11(2):173–180. https://doi.org/10.1134/s2079057021020077CrossRef

Labunets IF, Utko NA, Toporova OK, Savosko SI, Pokholenko IO, Panteleymonova TN, Butenko GM (2021c) Melatonin and fibroblast growth factor-2 potentiate the effects of human umbilical cord multipotent mesenchymal stromal cells in mice with cuprizone-induced demyelination [Article]. Biopolym Cell 37(5):369–378. https://doi.org/10.7124/bc.000A62CrossRef

Long T, Yang Y, Peng L, Li Z (2018) Neuroprotective Effects of Melatonin on Experimental Allergic Encephalomyelitis Mice Via Anti-Oxidative Stress Activity. J Mol Neurosci 64(2):233–241. https://doi.org/10.1007/s12031-017-1022-xCrossRefPubMed

Mahmoodi M, Sedghy F, Jafarzadeh A (2020) Effect of Treatment with Thyme Extract on Urinary Levels of Melatonin in an Experimental Autoimmune Encephalomyelitis Mouse Model. Rep Biochem Mol Biol 8(4):407–412PubMedPubMedCentral

Majidazar R, Rezazadeh-Gavgani E, Sadigh-Eteghad S, Naseri A (2022) Pharmacotherapy of Alzheimer’s disease: an overview of systematic reviews. Eur J Clin Pharmacol 78(10):1567–1587. https://doi.org/10.1007/s00228-022-03363-6CrossRefPubMed

Morsali S, Sabahi Z, Kakaei J, Hakimzadeh Z, Hamidi S, Gholipour-Khalili E, Sanaie S, Talebi M, Naseri A (2023) Clinical efficacy and safety of melatonin supplementation in multiple sclerosis: a systematic review. Inflammopharmacology 31(5):2213–2220. https://doi.org/10.1007/s10787-023-01271-4CrossRefPubMed

Muñoz-Jurado A, Escribano BM, Caballero-Villarraso J, Galván A, Agüera E, Santamaría A, Túnez I (2022) Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action. Inflammopharmacology 30(5):1569–1596. https://doi.org/10.1007/s10787-022-01011-0CrossRefPubMedPubMedCentral

Naseri A, Forghani N, Sadigh-Eteghad S, Shanehbandi D, Asadi M, Nasiri E, Talebi M (2022) Circulatory antioxidant and oxidative stress markers are in correlation with demographics but not cognitive functions in multiple sclerosis patients. Mult Scler Relat Disord 57:103432. https://doi.org/10.1016/j.msard.2021.103432CrossRefPubMed

Ortiz GG, Briones-Torres AL, Benitez-King G, Gonzalez-Ortiz LJ, Palacios-Magana CV, Pacheco-Moises FP (2022) Beneficial Effect of Melatonin Alone or in Combination with Glatiramer Acetate and Interferon beta-1b on Experimental Autoimmune Encephalomyelitis. Molecules. https://doi.org/10.3390/molecules27134217CrossRefPubMedPubMedCentral

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hróbjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https://doi.org/10.1136/bmj.n71CrossRefPubMedPubMedCentral

Preclinical Systematic Reviews & Meta-Analysis Wiki (2023) CAMARADES Berlin, QUEST-BIH Charité. https://www.CAMARADES.de

Potes Y, Cachán-Vega C, Antuña E, García-González C, Menéndez-Coto N, Boga JA, Gutiérrez-Rodríguez J, Bermúdez M, Sierra V, Vega-Naredo I, Coto-Montes A, Caballero B (2023) Benefits of the Neurogenic Potential of Melatonin for Treating Neurological and Neuropsychiatric Disorders. Int J Mol Sci. https://doi.org/10.3390/ijms24054803CrossRefPubMedPubMedCentral

Ramos Gonzalez EJ, Ramirez Jirano LJ, Garcia Martinez DZ, Ortiz GG, Jave Suarez LF, Leal Cortes CA, Bitzer Quintero OK (2021) A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis. Neurologia (Engl Ed) 36(4):262–270. https://doi.org/10.1016/j.nrl.2018.01.007CrossRefPubMed

Sharif R, Aghsami M, Gharghabi M, Sanati M, Khorshidahmad T, Vakilzadeh G, Mehdizadeh H, Gholizadeh S, Taghizadeh G, Sharifzadeh M (2017) Melatonin reverses H-89 induced spatial memory deficit: Involvement of oxidative stress and mitochondrial function. Behav Brain Res 316:115–124. https://doi.org/10.1016/j.bbr.2016.08.040CrossRefPubMed

Skarlis C, Anagnostouli M (2020) The role of melatonin in Multiple Sclerosis. Neurol Sci 41(4):769–781. https://doi.org/10.1007/s10072-019-04137-2CrossRefPubMed

Talebi M, Majdi A, Nasiri E, Naseri A, Sadigh-Eteghad S (2021) The correlation between circulating inflammatory, oxidative stress, and neurotrophic factors level with the cognitive outcomes in multiple sclerosis patients. Neurol Sci 42(6):2291–2300. https://doi.org/10.1007/s10072-020-04807-6CrossRefPubMed

Tobore TO (2021) Oxidative/Nitroxidative Stress and Multiple Sclerosis. J Mol Neurosci 71(3):506–514. https://doi.org/10.1007/s12031-020-01672-yCrossRefPubMed

Torkildsen O, Brunborg LA, Myhr KM, Bø L (2008) The cuprizone model for demyelination. Acta Neurol Scand Suppl 188:72–76. https://doi.org/10.1111/j.1600-0404.2008.01036.xCrossRefPubMed

Vakilzadeh G, Khodagholi F, Ghadiri T, Ghaemi A, Noorbakhsh F, Sharifzadeh M, Gorji A (2016) The Effect of Melatonin on Behavioral, Molecular, and Histopathological Changes in Cuprizone Model of Demyelination [Article]. Mol Neurobiol 53(7):4675–4684. https://doi.org/10.1007/s12035-015-9404-yCrossRefPubMed

Wen J, Ariyannur PS, Ribeiro R, Tanaka M, Moffett JR, Kirmani BF, Namboodiri AM, Zhang Y (2016) Efficacy of N-Acetylserotonin and Melatonin in the EAE Model of Multiple Sclerosis. J Neuroimmune Pharmacol 11(4):763–773. https://doi.org/10.1007/s11481-016-9702-9CrossRefPubMed

Zhan J, Mann T, Joost S, Behrangi N, Frank M, Kipp M (2020) The Cuprizone Model: Dos and Do Nots. Cells. https://doi.org/10.3390/cells9040843CrossRefPubMedPubMedCentral

Titel: The effects of melatonin supplementation on neurobehavioral outcomes and clinical severity in rodent models of multiple sclerosis; a systematic review and meta-analysis
verfasst von: Hadis Razmaray
Ehsan Nasiri
Pouya Vakilipour
Soroush Morsali
Afshin Moradi
Asal Ebrahimian
Sahel Rashidi
Reza Mosaddeghi-Heris
Saeed Sadigh-Eteghad
Amirreza Naseri
Publikationsdatum: 22.01.2024
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 2/2024
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-023-01414-7

Springer Medizin

Abstract

Background

Methods

Results

Discussion

Funding

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2024

Anti-rheumatoid arthritis potential of Halodule pinifolia: development, characterization and in vivo evaluation of H. pinifolia-based oral suspension and lipid nano-emulsion

PI3K/AKT signaling activation by roflumilast ameliorates rotenone-induced Parkinson’s disease in rats

Neuroprotective effect of curcumin against experimental autoimmune encephalomyelitis-induced cognitive and physical impairments in mice: an insight into the role of the AMPK/SIRT1 pathway

Sinomenine protects against atherosclerosis in apolipoprotein E-knockout mice by inhibiting of inflammatory pathway

Hexahydrocurcumin attenuated demyelination and improved cognitive impairment in chronic cerebral hypoperfusion rats

Does non-steroidal anti-inflammatory drugs-related preemptive analgesia modulate SOCS3/IL-6 pathway in oral surgery?